

PRODUCT: mTOR Inhibitor, WYE-132

ALTERNATE NAME: 1-{4-[1-(1,4-Dioxa-spiro[4.5]dec-8-yl)-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl}-3-methyl-urea; WYE-125132

CATALOG #: 2256-500, 1000

AMOUNT: 500 µg, 1 mg



MOLECULAR FORMULA: C₂₇H₃₃N₇O

MOLECULAR WEIGHT: 519.60

CAS NUMBER: 1144068-46-1

APPEARANCE: White solid

SOLUBILITY: DMSO (50 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: At -20° C. Protect from light and moisture

DESCRIPTION: Cell-permeable. A potent, selective, and ATP-competitive mTOR (mammalian Target Of Rapamycin) inhibitor (IC₅₀ = 0.19 nM). Displays >5000-fold selectivity over PI3Ks. WYE-132 inhibits mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo.

REFERENCE: Yu, K., *et al.* (2010). *Cancer Res.* **70**, 621-631.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

- BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
- BI-D1870 (Cat. No. 1824-1, 5)
- Deforolimus (Cat. No. 1587-5, 25)
- DiscoveryPak™ PI 3-Kinase Inhibitor Panel (Cat. No. K856-5)
- Everolimus (Cat. No. 1917-5, 25)
- GDC-0941 (Cat. No. 1623-1,5)
- GSK-2126458 (Cat. No. 1961-1, 5)
- IC87114 (Cat. No. 1661-1)
- LY 294002 (Cat. No. 1667-5, 25)
- mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1,5)
- mTOR Inhibitor, WYE-28 (Cat. No. 2255-500, 1000)
- PI-103 (Cat. No. 1728-1,5)
- PI3-K_γ Inhibitor, AS-605240 (Cat. No. 1780-1,5)
- PathwayReady™ PI3-K/Akt/mTOR Signaling Inhibitor panel (Cat. No. K857-11)
- PP242 (Cat. No. 1658-1)
- PX-866 (Cat. No. 1965-1,5)
- Rapamycin (Cat. No. 1568-5, 50)
- EZSolution™ Rapamycin (Cat. No. 1746-5)
- Temsirolimus (Cat. No. 1600-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1,5)
- Wortmannin (Cat. No. 1670)

USAGE: *FOR RESEARCH CH USE ONLY! Not to be used in humans*